ArticleJournal, genetic engineering & biotechnology2023
Preparation and characterization of spiked gold nanobipyramids and its antibacterial effect on methicillin-resistant Staphylococcus aureus and methicillin-sensitive Staphylococcus aureus.
Article in Journal, genetic engineering & biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Effect of Biosynthesized Gold and Silver Nanoparticles UsingAntibiotics (Basel, Switzerland) · 2026Article
- Article
- Dual function ofFrontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThis paper reports the preparation of a new family of spiked gold nanoparticles, spiked gold nanobipyramids (SNBPs). This protocol includes the process to synthesize gold nanobipyramids (NBPs) using combined seed-mediated and microwave-assisted method and procedure to form spikes on whole surface of gold nanobipyramid. We also evaluated the antibacterial activity against both methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus (MSSA) in various concentrations of SNBPs and NBPs by well diffusion assay, minimum inhibitory concentration (MIC), and minimum bactericidal concentration (MBC) determination. The effect of SNBPs on exposed bacteria was observed by scanning electron microscopy.
resultsThe UV-Vis of purified NBPs exhibited two absorption bands located at 550 nm and 849 nm with yield of bipyramidal particles more than 90%. The average size of NBPs was 76.33 ± 10.11 nm in length and 26.57 ± 2.25 nm in diameter, respectively, while SNBPs were prolongated in length and achieved 182.37 ± 21.74 nm with multi-branches protruding whole surface areas. In antibacterial evaluations, SNBPs and NBPs showed antibacterial activity with MIC of 6.25 μl/ml and 12.5 μl/ml, respectively, for MSSA while 12.5 μl/ml and 25 μl/ml, respectively, for MRSA. Besides, MBC values of SNBPs and NBPs were found to be 12.5 μl/ml and 25 μl/ml, respectively, against MSSA while 25 μl/ml and 50 μl/ml, respectively, against MRSA. Furthermore, scanning electron microscopy observation showed the mechanism that SNBPs damaged the outer membrane, released cytoplasm, and altered the normal morphology of MRSA and MSSA, leading to bacterial death.
conclusionsThis report suggests that these SNBPs are potential antibacterial agents that can be applied as antibacterial materials to inhibit the growth of human bacterial pathogen infections related to antibiotic-resistant bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.